What the FDA labels say about taking them together
Digoxin and siponimod
Siponimod's FDA label of June 30, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name siponimod. The siponimod label: “Experience with MAYZENT is limited in patients receiving concurrent therapy with drugs that decrease heart rate.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the siponimod FDA label on DailyMed (effective June 30, 2026, Novartis Pharmaceuticals Corporation).
What does the digoxin label say about siponimod?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name siponimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the siponimod label say about digoxin?
Siponimod label, drug interactionsBecause of the potential additive effects on heart rate, treatment with MAYZENT should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties, heart-rate lowering calcium channel blockers (e.g., verapamil, diltiazem), or other drugs that may decrease heart rate (e.g., ivabradine, digoxin) [see Warnings and Precautions (5.4) and Drug Interactions (7.3)].
Siponimod label, warnings and precautionsExperience with MAYZENT is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate, such as ivabradine and digoxin).
Source: FDA drug label (MAYZENT), Novartis Pharmaceuticals Corporation, effective June 30, 2026 (SPL set 44492772-5aed-4627-bd85-e8e89f308bb3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Siponimod | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Multiple sclerosis |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once